  Dose-adjusted rituximab plus etoposide , prednisone , vincristine , cyclophosphamide , and doxorubicin ( DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma ( PMBCL) , but predictors of resistance to this treatment are unclear. We investigated whether (